Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - empagliflozin; linagliptin - tablet - 10mg; 5mg - empagliflozin 10mg; linagliptin 5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - empagliflozin; linagliptin - tablet - 25mg; 5mg - empagliflozin 25mg; linagliptin 5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - empagliflozin; linagliptin - tablet, film coated - empagliflozin 10.00 mg; linagliptin 5.00 mg

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - empagliflozin; linagliptin - tablet, film coated - empagliflozin 25.00 mg; linagliptin 5.00 mg

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin, linagliptin - diabetes mellitus, type 2 - drugs used in diabetes - glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 10 mg - linagliptin and empagliflozin - jardiance 10mg is indicated: •to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.•as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus •to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 25 mg - linagliptin and empagliflozin - jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin; linagliptin - film coated tablets - linagliptin 5 mg; empagliflozin 10 mg - linagliptin and empagliflozin - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. limitations of useglyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin; linagliptin - film coated tablets - linagliptin 5 mg; empagliflozin 25 mg - linagliptin and empagliflozin - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. limitations of useglyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الادوية العربي - the arab drug store p.s.c - linagliptin 5 milligram/1 tablet, empagliflozin 25 milligram/1 tablet - 5 milligram/1 tablet, 25 milligram/1 tablet